Dr Reddy's anticipates recovery with semaglutide launch

Dr Reddy's Laboratories expects a gradual recovery in the current fiscal year after a profit decline last year. Growth in India, Europe, and emerging markets is offsetting pressures in the US business. New product launches and margin improvements are set to support expansion.

The company reported a drop in net profit for the previous fiscal year, primarily due to challenges in its US operations. In contrast, businesses in India, Europe, and emerging markets have demonstrated healthy growth momentum. Officials highlighted that these regions continue to perform well amid the broader recovery efforts.

Articoli correlati

Elderly woman with type 2 diabetes walking healthily outdoors, holding semaglutide pen, with subtle ENDO 2026 study charts in background
Immagine generata dall'IA

Study presented at ENDO 2026 links semaglutide to fewer fractures in people with type 2 diabetes

Riportato dall'IA Immagine generata dall'IA Verificato

Semaglutide was associated with a lower rate of bone fractures and greater reductions in body mass index among adults with type 2 diabetes, according to a retrospective analysis presented at the Endocrine Society’s ENDO 2026 meeting in Chicago.

Sun Pharmaceutical Industries posted robust revenue and profit increases for the March quarter. The company noted pressure on EBITDA margins due to higher investments and reduced milestone income. Outlook for the next fiscal year points to steady but moderated expansion.

Riportato dall'IA

Danish drugmaker Novo Nordisk is taking a local compounding pharmacy to court in Pretoria to stop the sale of unregistered semaglutide products. The High Court application targets iDexis over patient safety concerns.

Corporate India posted robust revenue increases during the March 2026 quarter. However, rising input costs and a weaker rupee pressured operating margins across many companies.

Riportato dall'IA

Market expert Sunil Subramaniam has advised caution for investors amid geopolitical uncertainty and rising input costs. He highlighted consumer durables, capital goods and public sector banks as preferred sectors.

In seguito ai risultati del 2025, che hanno mostrato un calo degli utili del 45,4% a causa dell'insolvenza nel settore agroalimentare, i dirigenti di Banco do Brasil hanno previsto al BB Day una ripresa a forma di 'W' per il settore nel 2026. L'indice di pagamento dovrebbe raggiungere il 95%, con l'insolvenza che continuerà a pesare sui risultati fino alla metà dell'anno a causa di rischi come le tensioni in Medio Oriente e il fenomeno El Niño. La banca manterrà prestiti calibrati sul rischio con garanzie più forti.

Riportato dall'IA

India's FMCG sector has posted a subdued performance in 2026, with the index down 10 percent year to date. Several leading companies have recorded double-digit declines amid geopolitical tensions and inflation.

 

 

 

Questo sito web utilizza i cookie

Utilizziamo i cookie per l'analisi per migliorare il nostro sito. Leggi la nostra politica sulla privacy per ulteriori informazioni.
Rifiuta